Title : A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.

Pub. Date : 2020 Mar

PMID : 32206706

1 Functional Relationships(s)
Compound Name
Protein Name
1 Here, a bi-adjuvant neoantigen nanovaccine (banNV) that codelivered a peptide neoantigen (Adpgk) with two adjuvants [Toll-like receptor (TLR) 7/8 agonist R848 and TLR9 agonist CpG] was developed for potent cancer immunotherapy. nanovaccine TLR9 Sus scrofa